Compare FormFactor Inc. FormFactor Inc. Common Stock (FORM) vs Royalty Pharma plc Class A Ordinary Shares (RPRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FormFactor Inc. FormFactor Inc. Common Stock vs Royalty Pharma plc Class A Ordinary Shares — how do they compare? FormFactor Inc. FormFactor Inc. Common Stock trades at $140.35 (market cap $10.92B), while Royalty Pharma plc Class A Ordinary Shares trades at $56.2 (market cap $25.27B). The key difference: Royalty Pharma plc Class A Ordinary Shares is far larger — about 2.3× FormFactor Inc. FormFactor Inc. Common Stock's market cap, and Royalty Pharma plc Class A Ordinary Shares pays a 1.66% dividend while FormFactor Inc. FormFactor Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold FormFactor Inc. FormFactor Inc. Common Stock for 0 Days and Royalty Pharma plc Class A Ordinary Shares for 0 Days on average.
| FORM | RPRX | |
|---|---|---|
Market Cap | $10.92B | $25.27B |
Volume | 1,056,924 | 3,671,183 |
Sector | Technology | Health |
52-Week High | $159.93 | $63.96 |
52-Week Low | $38.14 | $35.44 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $10.61B | $32.50B |
Dividend Yield | — | 1.66% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About FormFactor Inc. FormFactor Inc. Common Stock
FormFactor, Inc. provides semiconductor test and measurement technologies used across the integrated circuit lifecycle, manufacturing probe cards and analytical probes through its Probe Cards segment and probe stations, thermal systems, and cryogenic systems through its Systems segment.
Read more on FORM →About Royalty Pharma plc Class A Ordinary Shares
Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →
